Physician profile
Matko Kalac
NPI 1720378763
$62,363.22
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $6,968 · 2021: $2,234 · 2022: $23K · 2023: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $10K · Travel and Lodging: $3,332 · Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,442.50 |
| Consulting Fee | $10,125.00 |
| Travel and Lodging | $3,332.13 |
| Food and Beverage | $1,182.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $22,879.00 | 2020-2023 | Poteligeo |
| Seagen INC. | $22,148.32 | 2019-2023 | Adcetris |
| Acrotech Biopharma INC. | $8,633.53 | 2021-2023 | Beleodaq |
| Incyte Corporation | $4,070.00 | 2022 | |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $1,434.49 | 2019-2020 | |
| Janssen Research & Development, LLC | $748.65 | 2023 | |
| Amgen INC. | $424.00 | 2020 | |
| Eurofins Viracor, LLC | $187.91 | 2021 | |
| Tg Therapeutics, INC. | $137.32 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matko Kalac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.